Updates in pancreatic neuroendocrine carcinoma

Susan Alsamarai, Steven K. Libutti, Muhammad Wasif Saif

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Pancreatic neuroendocrine tumors display a range of clinical presentations and outcomes. Surgical resection remains the only potentially curative approach for primary tumors, and is also associated with a survival benefit for hepatic metastases as well. Data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting this year suggest that targeted agents may also play a role in advanced disease. Sunitinib, which targets VEGF-1, 2 and 3 and PDGF seems to be a well tolerated treatment for advanced tumors. The mTOR inhibitor everolimus when combined with the VEGF inhibitor bevacizumab, resulted in measurable responses. The combination of bevacizumab and cytotoxic chemotherapy also shows potential.

Original languageEnglish (US)
Pages (from-to)336-340
Number of pages5
JournalJournal of the Pancreas
Volume11
Issue number4
StatePublished - 2010

Fingerprint

Neuroendocrine Carcinoma
Vascular Endothelial Growth Factor A
Neuroendocrine Tumors
Neoplasms
Neoplasm Metastasis
Drug Therapy
Liver
Bevacizumab
Pancreatic Carcinoma
Therapeutics
Everolimus
sunitinib

Keywords

  • Bevacizumab
  • mTOR protein
  • Neuroendocrine tumors
  • Sunitinib

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Medicine(all)

Cite this

Alsamarai, S., Libutti, S. K., & Saif, M. W. (2010). Updates in pancreatic neuroendocrine carcinoma. Journal of the Pancreas, 11(4), 336-340.

Updates in pancreatic neuroendocrine carcinoma. / Alsamarai, Susan; Libutti, Steven K.; Saif, Muhammad Wasif.

In: Journal of the Pancreas, Vol. 11, No. 4, 2010, p. 336-340.

Research output: Contribution to journalArticle

Alsamarai, S, Libutti, SK & Saif, MW 2010, 'Updates in pancreatic neuroendocrine carcinoma', Journal of the Pancreas, vol. 11, no. 4, pp. 336-340.
Alsamarai S, Libutti SK, Saif MW. Updates in pancreatic neuroendocrine carcinoma. Journal of the Pancreas. 2010;11(4):336-340.
Alsamarai, Susan ; Libutti, Steven K. ; Saif, Muhammad Wasif. / Updates in pancreatic neuroendocrine carcinoma. In: Journal of the Pancreas. 2010 ; Vol. 11, No. 4. pp. 336-340.
@article{a5f56e8d60e04f09b1af21f8c3edf229,
title = "Updates in pancreatic neuroendocrine carcinoma",
abstract = "Pancreatic neuroendocrine tumors display a range of clinical presentations and outcomes. Surgical resection remains the only potentially curative approach for primary tumors, and is also associated with a survival benefit for hepatic metastases as well. Data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting this year suggest that targeted agents may also play a role in advanced disease. Sunitinib, which targets VEGF-1, 2 and 3 and PDGF seems to be a well tolerated treatment for advanced tumors. The mTOR inhibitor everolimus when combined with the VEGF inhibitor bevacizumab, resulted in measurable responses. The combination of bevacizumab and cytotoxic chemotherapy also shows potential.",
keywords = "Bevacizumab, mTOR protein, Neuroendocrine tumors, Sunitinib",
author = "Susan Alsamarai and Libutti, {Steven K.} and Saif, {Muhammad Wasif}",
year = "2010",
language = "English (US)",
volume = "11",
pages = "336--340",
journal = "Journal of the Pancreas",
issn = "1590-8577",
publisher = "E.S. Burioni Ricerche Bibliografiche",
number = "4",

}

TY - JOUR

T1 - Updates in pancreatic neuroendocrine carcinoma

AU - Alsamarai, Susan

AU - Libutti, Steven K.

AU - Saif, Muhammad Wasif

PY - 2010

Y1 - 2010

N2 - Pancreatic neuroendocrine tumors display a range of clinical presentations and outcomes. Surgical resection remains the only potentially curative approach for primary tumors, and is also associated with a survival benefit for hepatic metastases as well. Data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting this year suggest that targeted agents may also play a role in advanced disease. Sunitinib, which targets VEGF-1, 2 and 3 and PDGF seems to be a well tolerated treatment for advanced tumors. The mTOR inhibitor everolimus when combined with the VEGF inhibitor bevacizumab, resulted in measurable responses. The combination of bevacizumab and cytotoxic chemotherapy also shows potential.

AB - Pancreatic neuroendocrine tumors display a range of clinical presentations and outcomes. Surgical resection remains the only potentially curative approach for primary tumors, and is also associated with a survival benefit for hepatic metastases as well. Data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting this year suggest that targeted agents may also play a role in advanced disease. Sunitinib, which targets VEGF-1, 2 and 3 and PDGF seems to be a well tolerated treatment for advanced tumors. The mTOR inhibitor everolimus when combined with the VEGF inhibitor bevacizumab, resulted in measurable responses. The combination of bevacizumab and cytotoxic chemotherapy also shows potential.

KW - Bevacizumab

KW - mTOR protein

KW - Neuroendocrine tumors

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=77954780732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954780732&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 336

EP - 340

JO - Journal of the Pancreas

JF - Journal of the Pancreas

SN - 1590-8577

IS - 4

ER -